Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microchip-Based Device Detects Rare Tumor Cells in Bloodstream

By Labmedica staff writers
Posted on 09 Jan 2008
Scientists have developed a microchip-based device that isolates, counts, and analyzes circulating tumor cells (CTCs) from a blood sample.

CTCs are so hard to find that it has been impossible to adequately investigate their biology and significance. More...
Microchip-based technologies have the ability to accurately sense and sort specific types of cells, but have only been used with ml-sized fluid samples, the amount of blood in a fingerprick. Since CTCs are so rare, detecting them in useful quantities requires analyzing samples that are 1,000 to 10,000 times larger.

A team of investigators led by Mehmet Toner, Ph.D., from the Massachusetts General Hospital (MGH; Boston, MA, USA), investigated the factors required for microchip analysis of sufficiently large blood samples. The device they developed utilizes a business-card-sized silicon chip, covered with almost 80,000 microscopic posts coated with an antibody to a protein expressed on most solid tumors. The scientists also needed to calculate the correct speed and force with which the blood sample should pass through the chip to allow CTCs to adhere to the microposts. The new device--called the CTC-chip--has the potential to be an invaluable tool for monitoring and guiding cancer treatment.

The CTC-chip was tested against blood samples from 68 patients with five different types of tumors--lung, prostate, breast, pancreatic, and colorectal. A total of 116 samples were tested, and CTCs were identified in all but one sample, giving the test a sensitivity rating of 99%. No CTCs were found in samples from cancer-free control volunteers. To evaluate the device's ability to monitor response to treatment, blood samples were taken from nine cancer patients during their treatment for lung, colorectal, pancreatic, or esophageal tumors. Changes in levels of CTCs accurately reflected changes in tumor size as measured by standard computed tomography (CT) scans.

"This use of nanofluidics to find such rare cells is revolutionary, the first application of this technology to a broad, clinically important problem,” said Daniel Haber, M.D., director of the MGH Cancer Center. "While much work remains to be done, this approach raises the possibility of rapidly and noninvasively monitoring tumor response to treatment, allowing changes if the treatment is not effective, and the potential of early detection screening in people at increased risk for cancer.”

CTCs also can provide the molecular information needed to identify tumors that are candidates for the new targeted therapies and should help investigators to understand the biology of cancer cells and the mechanisms of metastasis.

The findings were reported in the December 20, 2007 issue of the journal Nature.


Related Links:
Massachusetts General Hospital

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.